Patient Name	Med Rec	#:
Requested By:		
Ordered By:		
Report Name:		
Surg Path Case - STATUS: Find		
**SEE NOTE	Collect/Perform:	
Ordered By:	Ordered Date:	
Facility:	Department:	
min all along the Benfamed Benn	 .	
Physician Who Performed Proced Requesting Physician:	dure:	

SURGICAL PATHOLOGY,		CASE#:
Attending Pathologist		
***********	*MODIFIED REPORT/ADDITIONAL	
RESULTS****************	****	
· · · · · · · · · · · · · · · · · · ·	99311	
HER-2/neu a Staining Score: 1+	ssay:	
Overexpression Assessment*	: NEGATIVE	
	*****	*****
******	****	
DIAGNOSIS:		
	.d buba lamamamania waaisal	huntarootoms and
 Uterus, cervix, ovaries an bilateral salpingo- 	id tube, laparoscopic vaginar	. Hysterectomy and
oophorectomy:		
•		
- High grade carcinoma of t	the endometrium.	
- The tumor is poorly diffe	erentiated, with some histolo	gic features
	oma. Tumor cells show no immu	noreactivity for
p53, BR and PR.	as half the phickman of the	mometrium
- Tumor invades less than on - Lymphovascular invasion is	ne half the thickness of the	myomecrian.
- No endocervical involvemen		
- See synoptic report below		
2. LEFT pelvic lymph nodes, k	piopsy:	
•		
- Sixteen lymph nodes, negat	ive for tumor (0/16).	

3. LEFT common lymph node, biopsy:

Corcinona, perses NOS 8441/3 Set: Endometrica 254.1 926/18/13

UUID: C975AESD-7370-4D1D-81AE-D3ABE5364055 TCGA-PG-A6IB-01A-PR Redacted

- Distant Metastasis (including abdominal lymph nodes): Cannot be

Pelvic nodes: 0/23 Para-aortic nodes: 0/4

determined

Patient Name:

Med Rec #:

Requested By: Ordered By:

Report Name:

- Additional Pathologic Findings: Adenomyosis

- Ancillary Studies:

ER (immunohistochemical stain): Negative PR (immunohistochemical stain): Negative

Other: P53 immunostain is negative

- AJCC Pathologic Staging: pTla NO M not applicable; FIGO: 1A

CLINICAL INFORMATION:

Uterine cancer.

GROSS DESCRIPTION:

1. The specimen is received fresh and labeled uterus, cervix, ovaries and tubes. It consists of a uterus, cervix with attached bilateral ovaries and fallopian tubes. The specimen weighs 107gram in toto and with following measurements: 8.5cm from fundus to exocervix; 5.0cm from cornu to cornu; 3.7cm from anterior to posterior. The right ovary and fallopian tube measures 2.2 x 1.0 x 0.7cm and 8.0 x 0.6 x 0.5cm, respectively. The left ovary and fallopian tube measures 2.4 x 1.2 x 0.7cm and 8.3 x 0.6 x 0.5cm, respectively. The exocervix is tan white and smooth. On opening, the endocervical canal measures 2.8cm in length and is a 0.6cm across. It has a tan unremarkable mucosa. The endometrial cavity measures 4.0cm in length and 3.5cm from cornu to cornu. The endometrium is tan and has a sessile polyploid tumor on the posterior wall, measuring 3.0 x 2.7 x 1.5cm. The tumor appears to be invasion of the underlying mucosa to a depth of 0.5cm of the myometrium. The myometrium measures 1.8cm in maximum thickness. The tumor is located 1.3cm from the lower uterine segment. Rest of the endometrium is tan-red, smooth and grosely unremarkable. There is a 1.0 cm of tan-white, rubbery and well-circumscribed leiomyoma within the myometrium. The right and left ovaries have a tan white smooth outer surface with several white corpora albicantia. The both fallopian tubes have grossly identifiable pinpoint lumen with fimbriated ends. Representative sections are submitted as follows:

- A: tumor with deepest invasion
- B: tumor with deepest invasion
- C: tumor with lower segment of the uterine
- D:
- E: posterior cervix
- F: anterior cervix
- G: anterior endometrium and myometrium

Page 3

Requested By Ordered By

Report Name:

H: leiomyoma

I-J: entire left ovary

K-M: entire left fallopian tube

N: entire right ovary

O-Q: entire right fallopian tube

2. The specimen is received fresh labeled "LEFT pelvic lymph nodes." It consists of fragments of tan-yellow and focally hemorrhagic adipose tissue measuring $4 \times 2 \times 1$ cm in aggregate. The specimen is submitted entirely as follows:

A - possible lymph nodes

B-C - remainder of adipose tissue

- 3. The specimen is received fresh labeled "LEFT common lymph node" and consists of a portion of tan-yellow adipose tissue measuring 1 x 0.6 x 0.3 cm. The specimen is submitted entirely in one cassette.
- 4. The specimen is received fresh labeled "RIGHT pelvic lymph nodes." It consists of fragments of tan-yellow and focally hemorrhagic adipose tissue measuring 3.5x 2 x 1 cm in aggregate. Possible intact lymph nodes are palpated and the specimen is entirely submitted in two cassettes.
- 5. The specimen is received fresh labeled "RIGHT para-aortic lymph nodes." It consists of fragments of tan-yellow and focally hemorrhagic adipose tissue measuring 2 \times 1.5 \times 0.5 cm in aggregate. Possible lymph nodes are palpated and the specimen is submitted entirely in one cassette.
- 6. The specimen is received fresh labeled "LEFT para-aortic lymph nodes" and consists of 3 fragments of tan-yellow adipose tissue measuring 1.3 \times 1.0 \times 0.3 cm in aggregate. Possible lymph nodes are palpated and the specimen is submitted entirely in one cassette.
- 7. The specimen is received fresh labeled "omentum" and consists of a portion of tan-yellow to tan-red adipose tissue measuring $4 \times 3 \times 0.6$ cm. The specimen is submitted entirely as follows:

A - possible lymph nodes B-C - remainder of fat

The following special studies were performed on this case and the interpretation is incorporated in the diagnostic report above: 1xESTROGEN RECEPTOR, 1xPROGESTERONE RECEPTOR, 1xP53, 1xHER-2-NEU POLY, HERCEPT

Page 4

Lent	Name

Med Rec #:

quested By: Ordered By:

sport Name:

** Electronic Signature **

**Electronically Signed Out by

I certify that I personally conducted the diagnostic evaluation of the above specimen(s) and have rendered the final diagnosis(es).

Note: The histology, immunochemistry and in situ hybridization components for this case were performed at

The Attending Pathologist reviewed this case and made the diagnosis.

Where applicable, immunohistochemistry and in situ hybridization tests were developed and the performance characteristics determined by the

have not been cleared or approved by the US Food and Drug Administration and the results should be correlated with other clinical and laboratory data. Appropriate controls were performed for all immunohistochemistry, in situ hybridization and histochemical tests.

Criteria 5/31//3 Yes No Diagnosis Discrepancy
Plimary Tumor Site Discrepancy
HIPAA Discrepancy
Prior Malignancy ristory
Dual/Syn-thronous Primary Affed
Case is (circls):
CualL'1EF Discrepance
Reviewer Initials